相关实验视频

Updated: Jul 8, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

韩国先进EGFR突变阳性非小细胞肺癌的现实世界一线阿法替尼:最新的生存数据

Juwhan Choi¹, Chang Min Choi², Yoon Soo Chang³

¹Division of Pulmonary, Department of Internal Medicine, Korea University Guro Hospital, Seoul, South Korea.

Translational lung cancer research

|December 13, 2023

概括

更新的生存数据显示,阿法替尼在韩国患者的EGFR突变非小细胞肺癌 (NSCLC) 中有效,平均总生存时间超过4年. 基线脑转移和不常见的EGFR突变与较差的结果有关.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
遗传学是一个遗传学.

背景情况:

阿法替尼在非小细胞肺癌 (NSCLC) 中表现出有效性,通过激活表皮生长因子受体 (EGFR) 突变.
韩国结核病和呼吸道疾病学院 (KATRD) EGFR队列的先前分析表明,阿法替尼在一线治疗中具有耐受性和令人鼓舞的有效性.
更新的生存数据来自KATRD EGFR队列,而此前的生存数据还不成熟.

研究的目的:

提供韩国先进EGFR突变阳性NSCLC患者的最新生存数据,这些患者接受了第一线阿法替尼治疗.
评估基线特征,包括大脑转移和特定EGFR突变,对无进展生存 (PFS) 和整体生存 (OS) 的影响.

主要方法:

对421名韩国成人患者的电子记录进行了回顾性,多中心的审查,这些患者患有先进的EGFR突变阳性NSCLC,开始了第一线阿法替尼.
使用卡普兰-梅尔生存曲线评估无进展生存 (PFS) 和整体生存 (OS).
根据基线大脑转移的存在,常见的 (Del19,L858R和T790M) EGFR突变,年龄和阿法替尼布剂量减少分层分析生存结果.

主要成果:

中位数PFS为20.2个月,中位数OS为48.6个月.
基线脑转移的存在显著降低了中位数PFS (14.9 vs. 28.0个月) 和OS (32.2 vs. 65.6个月).
常见的EGFR突变 (Del19,L858R) 与显著延长的中位数生存时间 (49.6 vs 30.1个月) 相关,而T790M突变与减少PFS有关,但与生存时间无关.

结论:

阿法替尼在韩国EGFR突变阳性NSCLC患者中有效,平均寿命超过4年.
基线脑转移和不常见的EGFR突变与降低的生存结果有关.
在没有基线脑转移的患者中,中位数的生存期超过了5年,这突显了这一预后因素的重要性.

关键词:

亚法替尼 (Afatinib) 是一种药物.皮肤上生长因子受体 (EGFR)第一个行第一行.非小细胞肺癌 (NSCLC) 是一种非小细胞肺癌.现实世界的真实世界.

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...